Institute for Systems Biology was founded in 2000 to invent the future as the first institute to pioneer systems science and its applications to biology and disease. ISB has made remarkable progress in its first 13 years.
We have pioneered the emergence of systems biology as a field, developing new strategies and applying them to fundamental problems in biology and medicine.
We have developed powerful new technologies (e.g. proteomics and genomics) and have pioneered a vast array of analytical tools for the life sciences.
We have applied systems thinking to the study of disease and catalyzed the development of a systems medicine that has already reached a tipping point and is changing the practice of healthcare, improving it, beginning to reduce its costs, and promoting innovation and the creation of new companies. The convergence of three major thrusts in healthcare—systems medicine, big data analysis and patient-activated social networks—has led to the emergence of a medicine that is predictive, preventive, personalized and participatory (P4 medicine) with the two major objectives of quantifying wellness and demystifying disease. P4 medicine will thus catalyze an ability to predict and prevent disease before it happens, empowering individuals with self-knowledge and catalyzing new dimensions of wellness. My own belief is that in the next 10 to 15 years, the wellness industry will grow to far exceed the healthcare industry.
The metrics for our success are many and are exemplified by two recent reports: The National Academy of Science published a report in 2009 on the “New Biology” that described systems biology perfectly and asserted it was the future for solving the fundamental problems of the life sciences—biology, healthcare, environment, agriculture, etc. The Spanish SCImago Institute has ranked almost 3,300 research institutions for the impact of their papers in all areas of science and ISB ranked fourth in the world in excellence of its papers. ISB’s papers cover biology, medicine, technology and computation/mathematics, reflecting the cross-disciplinary culture that lies at the heart of our success.
ISB invented the field of systems biology over the past decade. But how can we foster a new vision that will let us invent a transformational future? Although we are still debating this question, I want to discuss with you one proposal that fascinates me: pioneering the field of wellness.
I would like to propose that ISB catalyze a longitudinal study of 100,000 “well” individuals over 25 years, creating for each a virtual cloud of billions of data points that include (1) their genome sequences to identify actionable gene variants for which suggestions can be made for improving health; (2) longitudinal blood measurements two to three times a year for analysis with traditional clinical chemistries and assays that employ systems strategies (see below); and (3) high-frequency digital measurements coming from “quantified self” assessments that track exercise, sleep, stress, weight and nutrition.
The systems-driven assays that would enable us to track transitions from wellness to disease would include: (1) analyses of 10 or more organ-specific blood fingerprints that will allow us to track wellness in major organs including the brain, heart, liver, lung, etc.; (2) omics-characterizations of white blood cells to track inflammation and immune responses in each individual; (3) protein chips with 10,000 human proteins to identify autoantibodies (characteristic of autoimmune diseases such as rheumatoid arthritis and perhaps other diseases such as cancers and neurodegenerative diseases); and (4) track the human gut microbiome through stool analyses (which correlates in many different ways with wellness and susceptibility to diseases such as diabetes and heart disease).
These 100,000 virtual data clouds for individuals will provide invaluable data for optimizing wellness for each individual and they will permit us to identify effective metrics for assessing wellness of each individual, as well as markedly cut his or her costs for healthcare. In addition, we will see among these 100,000 patients transitions from wellness into major diseases. This will provide an early molecular warning for each of these diseases that will permit many to be managed more effectively. In the long run, we will accumulate massive amounts of information from these virtual data clouds that can be mined for the predictive medicine of the future. This effort would require the recruitment of patients from medical centers and community hospitals in the Seattle area, as well as research and academic centers to help develop the strategies, technologies and analytical tools necessary to generate and analyze these data. In the longer run, this database could provide information for spinning off diverse wellness and healthcare companies. This is a vision that could transform two massive industries and, indeed, make Seattle the Silicon Valley of the wellness market.
ISB is in a unique position to initiate such an effort, because it has been pioneering P4 medicine, with a focus on wellness; it has developed a variety of technologies that will contribute to diagnostic assays that will reveal new dimensions of patient data space; and it has strong computation and mathematical skills for acquiring, storing, mining, integrating and creating predictive and actionable models from each of the 100,000 virtual data clouds. It would be an exciting challenge for the scientists in all our labs to invent this future, utilizing powerful systems biology and systems medicine approaches to explore new dimensions of patient data space and develop new analytical tools to integrate and model the data.
In addition to the technical challenges, there would be striking societal challenges that could be the domain of the P4 Medicine Institute, a nonprofit institute dedicated to the fourth P—participatory—in P4 medicine. A key challenge is to develop a value proposition for healthcare consumers that would (1) engage them in using the actionable personalized health information which systems medicine can provide and (2) incentivize them to collect data that can be made available to mine for the predictive medicine of the future that will revolutionize healthcare for our children and grandchildren. Major questions would include how we can capture data in a way that is seamlessly incorporated in people’s daily lives; how to properly de-identify the data and protect people from abuses—which will involve additional legislation and regulatory action.
There are also striking challenges as to how we will educate patients, physicians, the healthcare community, payers and providers, and federal and state policy makers about the nature of this medicine. The solution will undoubtedly require the use of large-scale information technology. We will have to create a new profession of coaches who can bring insights gained from mining individual data clouds to individual patients. Finally, there is the challenge of funding this effort and identifying the types of organizations that should participate in this incredibly ambitious—and transformative—future.
There is no doubt in my mind this vision would further catalyze the profound paradigm change in healthcare that P4 medicine entails. This is a most ambitious new vision that would enable ISB to continue to invent the future through systems thinking around the strategies, technologies and analytics tools of P4 medicine and wellness.
Dr. Lee Hood, President and Co-Founder of ISB
Institute for Systems Biology’s mission is to revolutionize science and healthcare by using the power of systems biology to interrogate the complex molecular networks that govern wellness and disease. We are cultivating a global understanding and practice of the systems approach, which we pioneered and for which we serve as its most committed advocate. Here, we highlight nine headlines from 2012. Click on any of the images below to learn more.
Louis G. Lange,
MD, PHD
Chairman of the board
While the full impact of sequestration has yet to be seen, there’s no doubt that all nonprofit organizations are experiencing the challenges of facing reduced funding. ISB was able to increase total revenue in 2012, which is bright news in this difficult financial time. We have been diligent about cultivating our funding and contributor networks to ensure ISB can continue to achieve breakthroughs in deciphering some of the most complex diseases that affect our lives. We also have done the hard work of further streamlining our research operating expenses to help create a sustainable financial future.
Revenues | $ |
% |
---|---|---|
Grants & Contract Revenue | 37,018 |
80.1 |
Contributions | 6,737 |
14.6 |
Investment & Other Income | 2,480 |
5.4 |
Total Revenues | 46,235 |
100.0 |
Expenditures | $ |
|
Research & Other Direct Costs | 34,213 |
|
Management & General | 11,163 |
|
Fundraising & Other | 186 |
|
Total Expenditures | 45,562 |
|
Increase in Net Assets | 673 |
Assets | $ |
---|---|
Cash & Investments | 18,183 |
Other Assets | 10,007 |
Property & Equipment (Net) | 15,327 |
Total Assets | 43,517 |
Liabilities | $ |
Accounts Payable & Accrued Expenses | 18,710 |
Deferred Revenues | 4,287 |
Notes Payable | 8,344 |
Total Liabilities | 31,341 |
Net Assets | $ |
Unrestricted Net Assets | (308) |
Temporarily Restricted Net Assets | 3,812 |
Permanently Restricted Net Assets | 8,672 |
Total Net Assets | 12,176 |
$100,000+ |
---|
Arthur Vining Davis Foundations |
The Boeing Company |
William K. Bowes, Jr. Foundation |
Lee Hood and Valerie Logan |
Roger M. Perlmutter |
$25,000 - $99,999 |
---|
Complete Genomics, Inc. |
Franklin and Catherine Johnson |
Nesholm Family Foundation |
Sabey Corporation Dave and Sandra Sabey |
$10,000 - $24,999 |
---|
Amgen Foundation |
Integrated Diagnostics, Inc. |
Iverson Genetic Diagnostics, Inc. |
The Seattle Foundation |
Vulcan Real Estate |
The Adam J. Weissman Foundation |
$2,500 - $9,999 |
---|
Amgen, Inc. |
Mark Ashida and Lisbet Nilson |
Sissy and Tom Bouchard |
Carole Ellison |
Fenwick & West LLP |
Michael R. Flory |
Douglas Howe and Robin DuBrin |
Intellectual Ventures, Inc. |
Louis G. Lange |
LI-COR, Inc. |
Life Technologies Corporation |
Dan Ling and Lee Obrzut |
J. Leighton and Carol Read |
Ronald C. Seubert |
Georges C. St. Laurent, Jr. |
Cynthia Stroum |
Thermo Fisher Scientific, Inc. |
Touchstone Corporation |
Elaine and Larry Woo |
$1,000 - $2,499 |
---|
AB Sciex LLC |
Agilent Technologies, Inc. |
John and Leslie Aitchison |
Nitin Baliga and Janet Ceballos |
Bristol-Myers Squibb Company |
Thomas J. Cable |
Jim and Sherry Ladd |
Rob Lipshutz and Nancy Wong |
Nick Newcombe |
Gil Omenn and Martha Darling |
Patti Payne |
Simon Ramo |
Dana and Ben Riley Black |
Washington STEM |
$500 - $999 |
---|
Kasra R. Badiozamani |
Bruker Daltonics, Inc. |
Victoria Buker |
Sean and Lauren Clisham |
Evergreen Associates, Ltd. |
Myron and Sue Hood |
Chris Moe |
Victor Ng |
Nathan D. Price |
Proteome Software, Inc. |
The Satya & Rao Remala Foundation |
The Greer/Solien Fund |
Shawn and Jeff Swift |
Aron and Sara Thompson |
University of Victoria |
$250 - $499 |
---|
Katherine Barnett |
Ron and Gail Behar |
Suzanne M. Burke |
Roy and Mary Currence |
Renee Duprel |
Lynn and Michael Garvey |
Genalyte, Inc. |
Kevin Higman |
Bob and Rhoda Jensen |
Paul and Lucy Lange |
Sid and Heather Logan |
Mike and Lisa Losh |
Lisa Mayfield |
Lyle and Nancy Middendorf |
Kirsten Nesholm |
Amy and Matt Rudolf |
Ned and Allison Sander |
Carl and Carole Scandella |
Haeryung Shin and Andrew von Nordenflycht |
William A. Sperling |
Erich C. Strauss |
Thomas Weingarten and Wendy Thon |
Griffith Way |
$150 - $249 |
---|
Trudy Adkins |
Susan Adler |
Daniel V. Byrne |
Jan Chalupny |
JoAnn Chrisman |
Linette Demers |
Jennifer G. Dougherty |
Sandra L. Everlove |
Richard Gelinas |
Eran Hood and Sonia Nagorski |
Marqui Hood |
Dana Hurley |
Kathlyn Huson |
Inyoul Lee |
Sarah Li |
B Lippit |
Claudia and Adam Ludwig |
Bill and Anita Neil |
Marel Norwood |
Gary Owen |
Shizhen Qin |
Salal Credit Union |
Natasha Simkovich and Tim Hunt |
Social 27 |
Sergey Stolyar |
Peter and Shannon Van Oppen |
Janis Wignall |
Up to $149 |
---|
Eric and Audra Adelberger |
Anonymous |
Ryan Austin |
Martha W. Bond |
Lisa and Peter Boveng |
Mary Brunkow |
Hsiao-Ching Chou |
Jeanne Ting Chowning |
Michele Costa |
Ana Crossman |
Kori Dunaway |
Mary and Martin Ensley |
Jo Fiorito |
Elizabeth Fulwiler |
The Gill Family |
Gregory Hart |
Mary Alice Heuschel |
Charles L. Hirsch |
Ron and Mary Hjorth |
Bruce and Betty Ann Jansson |
Kim Klinke |
Kerstin Kramer |
Up to $149 (cont'd) |
---|
Mitchell and Hilde Kronenberg |
Gillia A. Lambert |
Mike Lemonde |
Laura Lockard |
Caroline Maillard |
Don McConkey |
Fidelma McGinn |
Bruce and Joanne Montgomery |
Lucy Olson |
Stephen Parris |
Kim Roeber |
Sherri Rogalski |
Lee Rowen |
Tracy L. Schmitz |
Bingyun Sun |
Qiang Tian |
Top Pot Doughnuts |
Cheryl Tuller |
Christine Tuller |
Victoria VanBruinisse |
Doral and David Vial |
Tayloe Washburn |
Kevin Washington |
Journal publications serve as an important metric of success for our scientists. In 2012, we had many high-impact papers, including research published in top journals Nature, Cell and Science.